Molnupiravir

No, Molnupiravir is not approved for use in children or patients below the age of 18 years as it may interfere with the growth of bones and cartilage.

Molnupiravir has better patient compliance than some other treatment options available against COVID-19. Unlike other medicines that may need a skilled healthcare professional (a doctor or a nurse) to administer, Molnupiravir is an oral medicine that can be consumed by mouth in the dosage and schedule prescribed by the doctor.

Yes, there are some serious risks involved with using Molnupiravir, including its potential to cause birth defects in pregnant women and serious damage to the growth of bones and cartilage (which may cause serious muscle damage). Therefore, Molnupiravir should be used only if prescribed by a doctor and not used for self-medication.

No. There is no comparison between the two, and Molnupiravir is not a substitute for getting vaccinated. Vaccination is for prevention, while Molnupiravir is used to treat an existing COVID-19 infection, provided the infection is diagnosed at an early stage.

People who are at a high risk of developing severe COVID-19 include those aged above 60 years, who are obese, have comorbid conditions including high blood pressure, diabetes, asthma, other medical conditions related to the lungs, kidneys (like dialysis patients), liver, or those who have a weak immunity (like cancer patients).

Molnupiravir should not be taken to prevent COVID-19 or treat patients hospitalized due to COVID-19. According to the ongoing clinical trials, patients hospitalized with severe COVID-19 infection have not benefited from taking Molnupiravir.